JAYDESS 13.5 mg, drug release system intrauterine
Active ingredients: Levonorgestrel
Commercialized according to BDPMDispensing in France: Prescription only
Drug release systemboîte de 1 dispositif suremballéintra-utérine
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- JAYDESS 13,5 mg, système de diffusion intra-utérin
- Pharmaceutical form
- système de diffusion
- Route of administration
- intra-utérine
- Presentation description
- boîte de 1 dispositif suremballé
- Marketing authorisation holder
- BAYER HEALTHCARE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 27 Nov 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
63905960CIP72741947CIP133400927419478Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉVONORGESTRELsystème de diffusion | 13,50 mg · un système de diffusion intra-utérin | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.